The latest update is out from Pharma Mar SA ( (ES:PHM) ).
PharmaMar’s Board of Directors has proposed a 23% increase in the dividend to 0.80 euros per share, reflecting the company’s financial strength and commitment to shareholder value. This marks the sixth consecutive year of dividend distribution, with a total accumulated amount exceeding 70 million euros, highlighting the company’s robust financial performance with an 11% revenue growth in 2024.
More about Pharma Mar SA
PharmaMar is a biopharmaceutical company specializing in the research and development of oncology treatments. It focuses on creating innovative medicines derived from marine sources to improve the health of patients with serious diseases. The company markets products like Yondelis® in Europe, Zepzelca® in the US, and Aplidin® in Australia, and has a strong R&D program in oncology.
YTD Price Performance: 17.76%
Average Trading Volume: 1,084
Technical Sentiment Signal: Sell
Current Market Cap: $1.73B
See more insights into PHM stock on TipRanks’ Stock Analysis page.